Regulatory approval

Published by the European Medicines Agency. Superseded

The European Medicines Agency (EMA) has authorized dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.

This is written in the approval document as:

JEMPERLI is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.

Citation

GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised June 2025. Accessed August 29, 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description
2024-10-20	Van Allen lab	Adding EMA approvals for use to database
2023-12-07	European Medicines Agency	Indication received approval from the European Commission.